Bayer Biological Products Launches New Global Headquarters, Announces Senior Leadership Team for Division.BERKELEY, Calif. -- Ceremony at Berkeley Site Heralds Expanded Commitment to Berkeley Area and Global Hemophilia hemophilia (hē'məfĭl`ēə,–fēl`yə), genetic disease in which the clotting ability of the blood is impaired and excessive bleeding results. Community Today, Bayer Biological Products (BP) celebrates the new global headquarters for its division, as well as the installment of Bayer BP's new leadership team. This team, who joins Joseph Akers continuing in his role as president of Bayer BP, will be officially announced today in a ceremony at the new Berkeley-based global headquarters. Today's event marks the launch of the new Bayer BP, following the successful divestiture The breakup of AT&T. By federal court order, AT&T divested itself on January 1, 1984 of its 23 operating companies, which became known as the Regional Bell Operating Companies (RBOCs). of the division's plasma protein plasma protein n. Any of the various dissolved proteins of blood plasma, including antibodies and blood-clotting proteins, that act by holding fluid in blood vessels by osmosis. business March 31, 2005. Bayer BP, which manufactures and markets the Kogenate(R) line of products (Kogenate(R) FS/KOGENATE(R) Bayer, Antihemophilic Factor an·ti·he·mo·phil·ic factor n. Abbr. AHF See factor VIII. antihemophilic factor (AHF, factor VIII) Alphanate, Hemofil M, Koate-DVI, Kogenate FS, Monarc-M, Monoclate-P, Recombinate, ReFacto (Recombinant recombinant /re·com·bi·nant/ (re-kom´bi-nant) 1. the new entity (e.g., gene, protein, cell, individual) that results from genetic recombination. 2. pertaining or relating to such an entity. See also under DNA. ), Formulated with Sucrose) for the treatment of hemophilia A hemophilia A n. Hemophilia due to deficiency of factor VIII, characterized by prolonged clotting time, decreased formation of thromboplastin, and diminished conversion of prothrombin. , remains a separate division within Bayer HealthCare. Mr. Akers and the new leadership team welcome to the ceremony VIPs from the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Government, the State of California, and the City of Berkeley. The event also showcases the recently initiated construction of a new clinical manufacturing facility, representing a $50 million capital investment by Bayer BP in the City of Berkeley. "California is a gateway to revolutionary biomedicine biomedicine /bio·med·i·cine/ (bi?o-med´i-sin) clinical medicine based on the principles of the natural sciences (biology, biochemistry, etc.).biomed´ical bi·o·med·i·cine n. 1. , and this center symbolizes the ingenuity that is the hallmark of our great state," said Governor Arnold Schwarzenegger Arnold Alois Schwarzenegger (German pronunciation (IPA): [ˈaɐ̯nɔlt ˈaloɪ̯s ˈʃvaɐ̯ʦənˌʔɛɡɐ] . "Bayer BP has been an esteemed Bay Area enterprise for more than 100 years and brings together the best in clinical research and medical innovation for the benefit of patients." "We are pleased Bayer is committed not only to continuing their operations here, but also to expanding their investment in both Berkeley and the state of California," said Secretary Sunne Wright McPeak of the state's Business, Transportation and Housing Agency. "Bayer's Berkeley facility has been a long-standing Bay Area enterprise, contributing significantly to community efforts for more than 100 years." On April 1, 2005, Mr. Akers and his leadership team officially took the helm of Bayer Biological Products. The team includes: --Paul Heiden continues as Senior Vice President of Technical Operations --Michael Fournel continues as Bayer BP's Senior Vice President of Research and Development --Martin VanTrieste (formerly head of Quality for the Berkeley site) becomes Vice President of Quality for Bayer BP --Carol Moore continues to serve as Vice President of Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: --Michael Mathews (formerly head of Global Strategic Marketing, Coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or ) assumes the role of Vice President, Global Marketing --Martin Dawkins continues as Vice President of Sales & Marketing for Europe region --Habib Dable (formerly Director of Worldwide Business Operations Business operations are those activities involved in the running of a business for the purpose of producing value for the stakeholders. Compare business processes. The outcome of business operations is the harvesting of value from assets with Bayer BP) becomes Vice President of Sales & Marketing for the regions Canada, Japan, and Developing Markets --Terry Tenbrunsel continues to lead the Kogenate(R) FS (Antihemophilic Factor (Recombinant), Formulated with Sucrose) U.S. Sales Organization --Rainer Schwarz (formerly Chief Administration Officer, Bayer HealthCare Group, Japan) becomes Vice President of Business Planning and Administration for Bayer BP --Justin Ford (formerly Director of Human Resources The fancy word for "people." The human resources department within an organization, years ago known as the "personnel department," manages the administrative aspects of the employees. for the Berkeley site) becomes Vice President, Organization Effectiveness (OE) for the entire BP Division --Julie Cheng (formerly Senior Counsel with Bayer Diagnostics) becomes Assistant General Counsel for Bayer BP "This new Bayer BP leadership team represents an outstanding group of experienced and customer-focused professionals," said Arthur Higgins, chairman of the executive committee of Bayer HealthCare. "This team, under Mr. Akers' leadership, will continue to grow Bayer BP's position in the global hemophilia marketplace." Bayer HealthCare has made it clear the Kogenate(R) line (Kogenate(R) FS/KOGENATE(R) Bayer, Antihemophilic Factor (Recombinant), Formulated with Sucrose) is one of the most valuable product areas in their business portfolio, representing an integral part of their long-term strategy. The company plans to focus additional resources toward the business, resulting in an increasing manufacturing and operational presence in the Berkeley area. "This is an exciting time for our business," said Mr. Akers. "We are poised for further expansion of our more than 30-year leadership position in the global hemophilia community through continued offerings of our current products and services, combined with a strong pipeline of technologies and products that will further advance hemophilia care." Mark Skinner, president, World Federation of Hemophilia, shared his excitement over the Bayer BP announcements. "The global hemophilia community is pleased Bayer BP is continuing its strong commitment to the hemophilia business and to advancing care through investments in R&D. We're looking forward to partnering with Bayer and the new leadership team to improve treatment and care for those living with hemophilia and enhance programs for both patients, as well as providers." Michael Mathews, newly designated vice president of Bayer BP Global Marketing, reinforced the company's expanded commitment to the global hemophilia community. "We have a unique vision of the future of hemophilia care, a future where people living with hemophilia have the freedom to fulfill their aspirations aspirations npl → aspiraciones fpl (= ambition); ambición f aspirations npl (= hopes, ambition) → aspirations fpl and live the lives they choose on their own terms. Our current and future products and technologies focus on improving convenience and ease of use that will move us toward this vision," explained Mr. Mathews. "Our customer-focused approach of listening and responding to unmet needs, has led us to strengthen existing programs and services while increasing investments in products and technologies that represent true breakthroughs for people living with hemophilia." As a recent example of pursuing true treatment breakthroughs, in December 2004, Bayer BP announced a deal with Zilip-Pharma to utilize their patented liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. technology to develop a longer-acting Kogenate(R) product that has the potential to be administered once weekly or less frequently. The new product could shift current treatment paradigms in hemophilia and simplify the lives of thousands of patients around the world. Bayer BP hopes to make the product available within five years, pending positive clinical results, required regulatory reviews, and necessary license approvals. Mr. Akers notes Berkeley is the perfect home for the division. The city and Bayer BP share a commitment to finding innovative ways to improve society, one community at a time. "We believe true corporate leadership means more than just providing safe and effective products," said Mr. Akers. "It's also about giving back. Building on our tradition of providing the most advanced hemophilia products and services, we will advance our leadership position through continued strong corporate citizenship Corporate Citizenship The extent to which businesses are socially responsible in meeting legal, ethical and economic responsibilities placed on them by shareholders. The aim it to create higher standards of living and quality of life in the community in which it operates, while ." About Bayer HealthCare AG Bayer HealthCare AG, a subsidiary of Bayer AG Bayer AG German chemical and pharmaceutical company. Founded in 1863 by Friedrich Bayer (1825–1880), it now operates plants in more than 30 countries. Bayer has originated scores of pharmaceuticals, chemicals, and synthetic materials; it was the first developer and , is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup sub·group n. 1. A distinct group within a group; a subdivision of a group. 2. A subordinate group. 3. Mathematics A group that is a subset of a group. tr.v. generated sales amounting to some 8.5 billion Euro. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004. Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease. Information about Bayer Biological Products Division can be found at www.bayerbiologicals.com. Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion